Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far
Executive Summary
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
You may also be interested in...
Novartis Sees Pliant’s NASH Program Offering Pathway To Treating Sickest Patients
Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.
Finance Watch: 14 Biopharma IPOs In One Remarkable Month
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Need a specific report? 1000+ reports available
Buy Reports